Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials - Wikidata - wikimedia - TriplyDB

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

http://www.wikidata.org/entity/Q24599547

about

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects.Targeted prodrug approaches for hormone refractory prostate cancer.Chemotherapy in Prostate Cancer.The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural Factor

P2860

Q37303584-7581A537-9225-48D7-9682-6A65E92F273A Q38295983-4B3849A7-B018-4B28-8508-B0495339549E Q38555599-77E8527A-92F4-49EC-BA4F-B63BBB403EDC Q47347786-B167A2DE-1906-4C76-8A8C-88C6C54CCEAC Q54631608-B697652B-6CD1-463D-958C-420CC43BA767 Q58993871-46F654D8-96DA-41CA-8A8B-23D42B274278

P2860

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials

http://www.wikidata.org/entity/Q24599547

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@ast

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@en

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@nl

type

label

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@ast

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@en

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@nl

prefLabel

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@ast

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@en

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@nl

P1433

Q24599547-7B58468A-3FCD-44A3-9970-A1F3E55E9C71

P1476

Q24599547-B63329D8-8026-446D-8BDA-DB49161C8FA8

P2093

Q24599547-42A31FB4-AF51-4894-AE8F-CBBED3D5FF18

Q24599547-4DF0641C-21D5-4342-BD14-8863885FBE24

Q24599547-6B740A38-3B61-4755-8722-E7F861E3097A

Q24599547-8D4322AA-5C35-4123-924B-8D05E993635C

Q24599547-92717136-0CA1-499C-8B07-AA82441B95F2

Q24599547-AE8026AC-2D96-4073-9EB3-6ECE63FE8FE6

P2860

Q24599547-368626A3-CCD8-4869-934C-07A490A25B0C

Q24599547-3BD009A3-2A62-45A4-9389-39E167EAF4EA

Q24599547-4816F9AF-0594-414C-B490-92A90A2B6084

Q24599547-49EA0945-D82D-4954-9A59-62A2EA026C28

Q24599547-4FAD2B9A-A416-4FE7-9C7C-913DA8D097AB

Q24599547-60B878CD-4976-440B-869B-7747A92FE087

Q24599547-60CCC00F-9293-448C-B7E4-45FCF70F76B0

Q24599547-68D3296D-08C9-498C-8871-61785EFE1ABA

Q24599547-782A95C0-9FFC-4F51-B99E-B10088833125

Q24599547-7CBC2875-5A89-45C3-86C0-66490A2A3D35

P304

Q24599547-542B94CA-67BD-410F-B8EA-004C06D7D87D

P31

Q24599547-23ab4c82-69b9-4b87-b93f-4501c5892737

Q24599547-9A2559AF-D73E-4790-A191-E79147446A42

P356

Q24599547-D6848983-B59F-46C8-8C75-EC70044D082F

P407

Q24599547-02FF6FE6-C927-4D8D-AEB6-1A587D367C76

P433

Q24599547-31B6E74E-E14D-4D97-BD0E-4E6A875DDFDF

P478

Q24599547-AB2CC370-1E1D-4E3F-A842-521E00EC27AC

P50

Q24599547-809B5A75-7E96-458D-8005-44FB778D5A61

Q24599547-ADB3F01B-92FA-4593-A13E-FF710DD62B56

P577

Q24599547-B1500AC5-8832-4FEF-8821-44F5D5795C36

P698

Q24599547-A8954A13-F0A4-470D-B825-247858B63858

P932

Q24599547-6813009D-8C10-48AB-8F81-3443523E89F1

P356

P1433

Annals of Oncology

P1476

Efficacy of carboplatin-taxane ...... en prospective clinical trials

@en

P2093

E K O'Donnell

http://www.w3.org/2001/XMLSchema#string

M M Regan

http://www.w3.org/2001/XMLSchema#string

N Kikuno

http://www.w3.org/2001/XMLSchema#string

S Urakami

http://www.w3.org/2001/XMLSchema#string

W Berry

http://www.w3.org/2001/XMLSchema#string

W K Kelly

http://www.w3.org/2001/XMLSchema#string

P2860

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.

Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.

Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer.

Meta-analysis: formulating, evaluating, combining, and reporting.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

P304

312-318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDP308

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19633053

http://www.w3.org/2001/XMLSchema#string

P932

2852201

http://www.w3.org/2001/XMLSchema#string